Max Robotics — Global Service Robot Directory + US Certification

About

Dr. S. Morganti is a pioneering researcher at the intersection of nuclear medicine and surgical robotics, specializing in radioguided surgery for prostate cancer. Their major contribution lies in the development and clinical validation of the DROP-IN beta probe, a novel device that integrates beta-emitting PET isotopes (like 68Ga-PSMA) with robotic-assisted surgery. This innovation addresses a critical limitation of traditional gamma probes, which rely on low-energy SPECT isotopes and lack the sensitivity needed for precise, real-time tumor detection. Morganti’s first ex vivo technology evaluation (2020, 43 citations) demonstrated the probe’s feasibility using prostate cancer specimens, laying the groundwork for intraoperative use. Their landmark first-in-human validation (2024, 14 citations) defined an optimal signal-to-background discrimination algorithm, proving the probe’s clinical utility in distinguishing malignant tissue from background. This work has the potential to transform prostate cancer surgery by enabling more complete resections while sparing healthy tissue. Morganti’s research bridges engineering, oncology, and nuclear medicine, offering a tangible solution to a pressing surgical challenge. With growing citation impact, their contributions are shaping the future of precision-guided robotic surgery.